ReviewWorld journal of gastroenterology2025
Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets.
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation-A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer remains one of the leading causes of cancer-related mortality worldwide, with hepatocellular carcinoma representing its most prevalent form. This review provides a comprehensive summary of the key factors driving the initiation and progression of hepatocellular carcinoma, with a particular emphasis on immune-related mechanisms. Furthermore, we delve into the emerging roles of galectins, particularly galectin-1 and galectin-3, in hepatocellular carcinoma pathobiology, underscoring their potential utility as biomarkers for assessing disease severity and progression. These insights contribute to a better understanding of the molecular and immunological underpinnings of hepatocellular carcinoma, paving the way for more targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.